Compare Johnson & Johnson (JNJ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Pfizer Inc — how do they compare? Johnson & Johnson trades at $259.29 (market cap $626.09B), while Pfizer Inc trades at $26.26 (market cap $151.73B). The key difference: Johnson & Johnson is far larger — about 4.1× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| JNJ | PFE | |
|---|---|---|
Market Cap | $626.09B | $151.73B |
Volume | 6,156,228 | 29,869,932 |
Sector | Health | Health |
52-Week High | $267.24 | $28.56 |
52-Week Low | $172.78 | $23.60 |
Enterprise Value | $654.37B | $203.22B |
Dividend Yield | 2.06% | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
